Catalysis
CompanySpain
Catalysis develops 3 assets, the furthest in phase 3, no development reported (Diamel in insulin resistance). Mostly supplement and small molecule; based in Spain.
- 3
- Assets
- Furthest stage
- Phase 3, no development reported
- 8
- Trials
- 13
- Signals
Pipeline
3Phase 3, no development reported, Supplement, insulin resistance, metabolic dysfunction-associated steatohepatitis
Inhibits HMGB1 activity and has anti-inflammatory and antiviral effects.
Phase 3, no development reported, Small molecule, papilloma viral infection, CIN1
Phase 3, no development reported, Supplement, chronic hepatitis c, cirrhosis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms4
- Trials8
- Signals20
- Integrity notices10
- Similar companies6